EUVIMEDEUVIMED entdecken
Open Access

Engineering of layer-by-layer acetate-coated paclitaxel loaded poly(lactide-co-glycolide) acid nanoparticles for prostate cancer therapy- in vitro

Albert Nguessan Ngo, Kierston K Chatman, Dezirae Douglas, Keb M Mosley-Kellum, Ke Wu, Jaydutt Vadgama

Journal of Pharmaceutical Sciences · 2024-11 · 113 (11) · 3375-3383

DOI: 10.1016/j.xphs.2024.09.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2024-11. Verfasst von Albert Nguessan Ngo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Division of Pharmaceutical Sciences, Tallahassee…. Hauptthemen laut MEDLINE: Paclitaxel, Prostatic Neoplasms, Nanoparticles, Antineoplastic Agents, Phytogenic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS, National Institute on Minority Health and Health Disparities, Florida Agricultural and Mechanical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is hypothesized that layer-by-layer acetate-coated Paclitaxel-loaded PLGA nanoparticles (F2) can be engineered to potentiate the effectiveness of Paclitaxel (PTX) on LNCaP, a human prostate cancer cell line. The core of the layer-by-layer NPs is formed by nanoprecipitation, and the shell of the NPs is engineered using the sodium acetate's unique coating mechanism and surface-active properties. The resulting nanoformulation physicochemical properties are characterized by Fourier Transform Infra-Red (FTIR), Differential Scanning Calorimetry (DSC) Transmission Electron Microscopy (TEM), NanoSight NS300, spectrophotometry, Korsmeyer-Peppas model, respectively. The NP's cytotoxicity on LNCaP is assessed by MTS assay. The DSC and the FTIR confirm SA's coating of the NPs. The particle's mean diameters (PMD) are 89.4±2.3- to 114.4±7.6 nm. The TEM shows a unique multilayer and spherical nanoparticle. The encapsulation efficiency of commonly PTX-loaded PLGA NPs (F1) and F2 are 84.37±2.71% and 86.74±2.22, respectively. The drug transport mechanism of F1 and F2 is anomalous transport and case II, respectively. F2 follows a zero-order release mechanism. The cell viability is 45.08±2.18% and 60.17±4.72% when LNCaP is treated with 10 µg/mL of F2 and F1, respectively, after 48 hours of exposure. F2 and F1 cell growth inhibition are dose-dependent. This unique process of engineering the layer-by-layer NPs will provide new horizons for developing future innovative nanoparticles for targeted prostate cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelProstatic NeoplasmsNanoparticlesAntineoplastic Agents, PhytogenicMaleHumansCell Line, TumorPolylactic Acid-Polyglycolic Acid CopolymerCell SurvivalDrug CarriersLactic AcidAcetatesParticle SizePolyglycolic Acid

Stichwörter der Autor:innen

CoatingDrug delivery systemLayer-by-layer nanoparticlesNanotechnologyProstate cancerSodium acetateTargeted therapy

Substanzen

PaclitaxelAntineoplastic Agents, PhytogenicPolylactic Acid-Polyglycolic Acid CopolymerDrug CarriersLactic AcidAcetatesPolyglycolic Acid

Autor:innen und Institutionen

  • Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Division of Pharmaceutical Sciences, Tallahassee, FL 32307, United States. Electronic address: albert.ngo@famu.edu.
  • Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Division of Pharmaceutical Sciences, Tallahassee, FL 32307, United States.
  • Charles R. Drew University of Medicine and Science, United States.

Förderung

  • NIMHD NIH HHS
  • National Institute on Minority Health and Health Disparities
  • Florida Agricultural and Mechanical University
  • Charles R. Drew University of Medicine and Science
  • American Cancer Society

Zitieren

APA

Ngo, A. N., Chatman, K. K., Douglas, D., Mosley-Kellum, K. M., Wu, K., & Vadgama, J. (2024). Engineering of layer-by-layer acetate-coated paclitaxel loaded poly(lactide-co-glycolide) acid nanoparticles for prostate cancer therapy- in vitro. Journal of Pharmaceutical Sciences, 113(11), 3375-3383. https://doi.org/10.1016/j.xphs.2024.09.014

Vancouver

Ngo AN, Chatman KK, Douglas D, Mosley-Kellum KM, Wu K, Vadgama J. Engineering of layer-by-layer acetate-coated paclitaxel loaded poly(lactide-co-glycolide) acid nanoparticles for prostate cancer therapy- in vitro. Journal of Pharmaceutical Sciences. 2024;113(11):3375-3383. doi:10.1016/j.xphs.2024.09.014

BibTeX
@article{Ngo2024,
  author = {Ngo, Albert Nguessan and Chatman, Kierston K and Douglas, Dezirae and Mosley-Kellum, Keb M and Wu, Ke and Vadgama, Jaydutt},
  title = {Engineering of layer-by-layer acetate-coated paclitaxel loaded poly(lactide-co-glycolide) acid nanoparticles for prostate cancer therapy- in vitro},
  journal = {Journal of Pharmaceutical Sciences},
  year = {2024},
  volume = {113},
  number = {11},
  pages = {3375--3383},
  doi = {10.1016/j.xphs.2024.09.014}
}
Kostenlos starten →